You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The book discusses recent findings and current perspectives on therapeutic angiogenesis. Studies have shown that therapies such as cell implantation and transfer of gene encoding for angiogenic growth factors are effective in improving symptoms in patients with critical limb ischemia, who previously had no treatment option other than amputation. The book discusses these therapies and presents data collected in clinical studies over the past decade. Despite significant advances in therapeutic angiogenesis since the first clinical studies in the early 21st century, it has been largely ignored in the literature. This comprehensive book fills that gap, making it a valuable resource for both researchers and practitioners alike.
The disease of the heart muscle may occur secondarily to common diseases, such as ischemic, hypertensive and valvular, among others. However, there is a group of conditions with intrinsic myocardial involvement from gene or multifactorial etiology, and high morbidity and mortality that represent a diagnostic and therapeutic challenge for the physician. The book is focused on these cardiomyopathies, its features, its pathophysiology and its relation to sudden death. Mention is made also on general aspects, like ecocardiographic findings and myocardial contractile reserve, specific as pathophysiology and molecular mechanisms and cardiomyopathies in special populations. Special attention was deserved to cardiomyopathies in pediatrics, diabetic patients and women, as well as to the cases of chronic heart failure and dilated cardiomyopathy.
The American Heart Association’s Scientific Sessions 2019 is bringing big science, big technology, and big networking opportunities to Philadelphia, Pennsylvania this November. This event features five days of the best in science and cardiovascular clinical practice covering all aspects of basic, clinical, population and translational content.
The American Heart Association’s Scientific Sessions 2016 is bringing big science, big technology, and big networking opportunities to New Orleans, Louisiana this November. This event features five days of the best in science and cardiovascular clinical practice covering all aspects of basic, clinical, population and translational content.
Human embryos, it has been said, "have no muscles, nerves, digestive system, feet, hands, face, or brain; they have nothing to distinguish them as a human being, and if one of them died, no one would mourn as they would for one of us." Consequently, early human embryos are being dismembered in laboratories around the world to produce embryonic stem cells, which, we are told, are the tools that will lead to the next quantum leap in medicine. Should Christians support such small sacrifices for something that might potentially relieve the suffering of millions, or should we vigorously oppose it? Developmental biologist and professor of biochemistry Michael Buratovich was asked such a question (...
Recent trends in Nanomedicine and Tissue Engineering covers numerous recent technological and research accomplishments in the area of Nanomedicine and Tissue Engineering. The introduction of nanomaterials and nanotechnology have led to crucial advancements in the fields of nanomedicine and tissue engineering, as well as cancer therapies and drug delivery systems.The book follows recent trends in drug delivery systems, wound healing fields, cancer therapies, protection of teeth and also other health care systems.Technical topics discussed in the book include:• Nanorobots• Tissue engineering• Gene therapy• Drug delivery• Nanomotors• Nanogels.
Small changes can make a big difference! This book will make you a believer that no matter what your age or state of health, you can live younger and healthier with greater energy, strength and clarity. By reading this book you will: - Unlock the motivators that make change possible and propel you through any obstacles - Understand the impact of your choices on your metabolism and overall health - Implement simple steps to make big changes - Discover why, what and how to transform your health and life - Begin to understand how you can leverage your unique metabolic and genetic code to take your health to a whole new level Written by an expert with a diverse background who developed award-winning programs for Fortune 100 companies, it is packed with practical advice you can implement immediately. Why wait? Don't just survive--thrive! You can live younger now!
The first unequivocal success for Gene Therapy was reported in April 2000 for X-SCID patients. Pioneering stem cell/gene therapy clinical trials are the focus of this book. Therapy successes such as the X-SCID trial and improved ADA-SCID ones are presented together with pioneering angio/vasculogenic clinical trials mediated either by transient gene therapy or emerging autologous stem cell transplantation. Highlights also include 1) promises of the breakthrough combination of stem cell- and transient gene-therapy, 2) gene therapy trials for neurodegenerative disease on non-human primates where long-term gene therapy might involve brain stem cells, and 3) the first clinical trial with non-invasive monitoring of therapeutic gene expression as a prospective conclusion.
These proceedings not only summarized the scientific and technological achievements in atherosclerosis research during the 20th century but also include the latest topics for future progress and development in this new millennium, highlighting the recent advances in vascular biology, angiogenesis and atherogenesis, pathogenesis of metabolic syndrome. The articles also encompass vast range of clinical and basic research field of atherosclerosis, including epidemiology, lipoprotein metabolism, pharmacology, clinical trials, nutrition, pathogenesis, diagnosis and prevention as well as its treatment.
This book describes the latest research on the gut-kidney axis of ureic solutes; the toxico-pathological mechanisms of uremic toxin-induced organ failure, including kidney and cardiovascular tissue; and the preventive therapeutic strategies for uremia and related organ failure associated with kidney injuries and diseases. Retained uremic toxins cause a variety of symptoms, such as hypertension, fatigue, renal anemia, osteoporosis and neurologic impairment, which are apparent in chronic kidney disease (CKD) patients. The human gastrointestinal tract contains trillions of microorganisms, referred to as gut microbiota, which support the host metabolism by producing nutrients, such as vitamins and short-chain fatty acids. However, they also produce various harmful uremic toxins that show renal and cardiovascular toxicity, and correlate with an increased mortality in CKD patients. The composition and balance of gut microbiota are associated with the accumulation of uremic toxins and the pathophysiology of CKD, and as such are being considered for a novel therapeutic strategy.